<p>Shield Therapeutics plc (LON:STX - 获取免费报告) 的股价在周二的交易中跌破了其 50 日移动平均线。该股的 50 日移动平均线为 GBX 9.39，最低交易价为 GBX 7.50。Shield Therapeutics 的股票最后交易价为 GBX 7.75，成交量为 5,318,340 股。</p>
<p>获取 <strong>Shield Therapeutics</strong> 的提醒：</p>
<h2>Shield Therapeutics 股价上涨 8.7%</h2>
<p>该公司的负债权益比为-182.06，速动比率为 2.16，流动比率为 0.83。该公司的市值为 9174 万英镑，市盈率为-4.30，贝塔系数为 1.91。该股的 50 日简单移动平均线为 GBX 9.39，200 日简单移动平均线为 GBX 9.04。</p>
<h2>Shield Therapeutics 公司简介</h2>
<p>(获取免费报告)</p>
<p>Shield 是一家商业阶段的专业制药公司，提供 Accrufer®/Feraccru®（铁麦芽糖），这是一种创新且差异化的药品，旨在满足铁缺乏症患者（无论是否伴有贫血）的重大未满足需求。该公司已在美国推出 Accrufer®，并与 Viatris Inc（Viatris）签署了独家多年的商业协议。在美国以外，该公司已将权利授权给四家专业制药公司。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Shield Therapeutics</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Shield Therapeutics 吗？</h2>
<p>在考虑投资 Shield Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Shield Therapeutics 并不在名单上。</p>
<p>虽然 Shield Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SEELQ

NBSE.ESC

PSTV

SEEL

<p>Shield Therapeutics（伦敦证券交易所代码：STX）股价跌破其 50 日移动平均线 9.39 便士，最低交易价为 7.50 便士，最终收于 7.75 便士。该股票的交易量为 5,318,340 股。公司市值为 9174 万英镑，市盈率为-4.30，负债权益比为-182.06。尽管分析师给予 “买入” 评级，但 Shield Therapeutics 并不是顶级分析师推荐的股票之一</p>

<p>Shield Therapeutics plc (LON:STX - Get Free Report)'s stock price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 9.39 and traded as low as GBX 7.50. Shield Therapeutics shares last traded at GBX 7.75, with a volume of 5,318,340 shares changing hands.</p>
<div class="lb-trans"><p>Shield Therapeutics plc (LON:STX - 获取免费报告) 的股价在周二的交易中跌破了其 50 日移动平均线。该股的 50 日移动平均线为 GBX 9.39，最低交易价为 GBX 7.50。Shield Therapeutics 的股票最后交易价为 GBX 7.75，成交量为 5,318,340 股。</p>
</div><p>Get <strong>Shield Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Shield Therapeutics</strong> 的提醒：</p>
</div><h2>Shield Therapeutics Trading Up 8.7%</h2>
<div class="lb-trans"><h2>Shield Therapeutics 股价上涨 8.7%</h2>
</div><p>The company has a debt-to-equity ratio of -182.06, a quick ratio of 2.16 and a current ratio of 0.83. The firm has a market capitalization of £91.74 million, a PE ratio of -4.30 and a beta of 1.91. The stock's 50-day simple moving average is GBX 9.39 and its 200-day simple moving average is GBX 9.04.</p>
<div class="lb-trans"><p>该公司的负债权益比为-182.06，速动比率为 2.16，流动比率为 0.83。该公司的市值为 9174 万英镑，市盈率为-4.30，贝塔系数为 1.91。该股的 50 日简单移动平均线为 GBX 9.39，200 日简单移动平均线为 GBX 9.04。</p>
</div><h2>Shield Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Shield Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.</p>
<div class="lb-trans"><p>Shield 是一家商业阶段的专业制药公司，提供 Accrufer®/Feraccru®（铁麦芽糖），这是一种创新且差异化的药品，旨在满足铁缺乏症患者（无论是否伴有贫血）的重大未满足需求。该公司已在美国推出 Accrufer®，并与 Viatris Inc（Viatris）签署了独家多年的商业协议。在美国以外，该公司已将权利授权给四家专业制药公司。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Shield Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Shield Therapeutics</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Shield Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Shield Therapeutics 吗？</h2>
</div><p>Before you consider Shield Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Shield Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shield Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Shield Therapeutics 并不在名单上。</p>
</div><p>While Shield Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Shield Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Shield Therapeutics (LON:STX) 的股价跌破了 50 日移动平均线 - 接下来会发生什么？